Last reviewed · How we verify

NCT05961956

Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis

Active, enrolled Phase 1, PHASE2 Last updated 24 December 2025
What this trial tests

Phase 1, PHASE2 trial testing NVDX3 in Degenerative Lumbar Spondylolisthesis in 5 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
12 October 2023
Primary endpoint
18 April 2026
18 April 2026

Quick facts

Lead sponsorNovadip Biosciences
PhasePhase 1, PHASE2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment5
Start date12 October 2023
Primary completion18 April 2026
Estimated completion18 April 2026
Sites1 location across Luxembourg

Drugs / interventions tested

Conditions studied

Sponsor

Novadip Biosciences — full company profile →

Who can join

Adults 18 to 80, any sex, with Degenerative Lumbar Spondylolisthesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, single arm, single-center clinical study to test NVDX3 in patients suffering from low grade one level degenerative lumbar (L1 - S1) spondylolisthesis. NVDX3 will be implanted during a single surgical intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of NVDX3

Trials testing the same drug.

Other recruiting trials for Degenerative Lumbar Spondylolisthesis

Currently open trials in the same condition.

Other Novadip Biosciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05961956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing